{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Conditioning&page=3",
    "query": {
      "condition": "Conditioning",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 564,
    "total_pages": 57,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Conditioning&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Conditioning&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T05:04:44.080Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00924287",
      "title": "Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2008-11",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2015-10-28",
      "last_synced_at": "2026-10-20T05:04:44.080Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00924287"
    },
    {
      "nct_id": "NCT02661035",
      "title": "Allo HSCT Using RIC for Hematological Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Acute Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia",
        "Plasma Cell Leukemia",
        "Myelodysplastic Syndromes",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "B-Cell Lymphoma",
        "Follicular Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Mantle-Cell Lymphoma",
        "Prolymphocytic Leukemia",
        "Lymphoblastic Lymphoma",
        "Burkitt's Lymphoma",
        "Non-Hodgkin's Lymphoma",
        "Multiple Myeloma",
        "Myeloproliferative Syndromes",
        "Hematological Diseases"
      ],
      "interventions": [
        {
          "name": "Allopurinol",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "ATG",
          "type": "DRUG"
        },
        {
          "name": "TBI",
          "type": "RADIATION"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "MMF",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Related or Unrelated Bone Marrow Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 156,
      "start_date": "2017-03-09",
      "completion_date": "2023-05-29",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-20T05:04:44.080Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02661035"
    },
    {
      "nct_id": "NCT00368355",
      "title": "T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Non Hodgkins Lymphoma",
        "Myelodysplastic Syndrome",
        "Acute Myeloid Leukemia",
        "Chronic Myelogenous Leukemia",
        "Hemophagocytic Lymphohistiocytosis (HLH)",
        "Familial Hemophagocytic Lymphohistiocytosis (FLH)",
        "Viral-associated Hemophagocytic Syndrome (VAHS)",
        "X-linked Lymphoproliferative Disease (XLP)"
      ],
      "interventions": [
        {
          "name": "Ara-C",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Campath-1H",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Stem Cell Infusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 46,
      "start_date": "2000-04",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2020-01-21",
      "last_synced_at": "2026-10-20T05:04:44.080Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00368355"
    },
    {
      "nct_id": "NCT00553306",
      "title": "Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "OTHER",
        "GENETIC"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2007-09",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2017-02-15",
      "last_synced_at": "2026-10-20T05:04:44.080Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00553306"
    },
    {
      "nct_id": "NCT02043847",
      "title": "TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma, Relapsed",
        "Multiple Myeloma, Refractory to Standard Treatment"
      ],
      "interventions": [
        {
          "name": "Total Marrow Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim (G-CSF)",
          "type": "DRUG"
        },
        {
          "name": "Autologous transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-01-14",
      "completion_date": "2016-09-14",
      "has_results": true,
      "last_update_posted_date": "2024-11-13",
      "last_synced_at": "2026-10-20T05:04:44.080Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02043847"
    },
    {
      "nct_id": "NCT01969435",
      "title": "Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Disease",
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide phosphate",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan HCl (propylene glycol-free)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2014-03-19",
      "completion_date": "2017-05-31",
      "has_results": true,
      "last_update_posted_date": "2018-02-13",
      "last_synced_at": "2026-10-20T05:04:44.080Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01969435"
    },
    {
      "nct_id": "NCT01235793",
      "title": "The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-Cell Lymphoma Originating in the CNS"
      ],
      "interventions": [
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 11,
      "start_date": "2010-10-14",
      "completion_date": "2018-04-18",
      "has_results": true,
      "last_update_posted_date": "2018-11-20",
      "last_synced_at": "2026-10-20T05:04:44.080Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01235793"
    },
    {
      "nct_id": "NCT01471652",
      "title": "Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Fatigue Syndrome"
      ],
      "interventions": [
        {
          "name": "Nutraceutical supplements",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "25 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2012-03",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2015-04-13",
      "last_synced_at": "2026-10-20T05:04:44.080Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01471652"
    },
    {
      "nct_id": "NCT03512028",
      "title": "Remote Limb Ischemic Conditioning to Enhance Learning and Muscle Strength in Healthy Young Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy, Young Adults"
      ],
      "interventions": [
        {
          "name": "RLIC",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Sham conditioning",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Muscle strength training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Driving training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Balance training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 34,
      "start_date": "2017-11-08",
      "completion_date": "2019-01-31",
      "has_results": true,
      "last_update_posted_date": "2020-02-05",
      "last_synced_at": "2026-10-20T05:04:44.080Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03512028"
    },
    {
      "nct_id": "NCT03534739",
      "title": "Pain Modulatory Profiles in Massage for Individuals With Neck Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Musculoskeletal Pain",
        "Neck Pain"
      ],
      "interventions": [
        {
          "name": "Pain Inducing Massage",
          "type": "OTHER"
        },
        {
          "name": "Light Touch Massage",
          "type": "OTHER"
        },
        {
          "name": "Coldpressor",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 26,
      "start_date": "2018-06-20",
      "completion_date": "2022-06-09",
      "has_results": false,
      "last_update_posted_date": "2022-07-07",
      "last_synced_at": "2026-10-20T05:04:44.080Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03534739"
    }
  ]
}